Editing genes to treat disease
Editas Medicine was one of the first CRISPR companies, co-founded by Feng Zhang. The company focuses on gene editing medicines using both Cas9 and Cas12a nucleases, with programs in eye disease and cancer immunotherapy.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| EDIT-101 | Leber Congenital Amaurosis 10 | Phase 1/2 | CRISPR-Cas9 |
| EDIT-301 | Sickle Cell Disease | Phase 1/2 | CRISPR-Cas12a |
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.